New Delhi: US drugmaker Eli Lilly is expected to launch its oral weight‑loss pill Orforglipron in India. If introduced, it will expand access to obesity
treatment. It may be noted that the drug may be launched at a time when obesity drugs are being extensively sold in India.
Speaking to Moneycontrol, Winselow Tucker, President and General Manager, Eli Lilly and Company (India), said the pharmaceutical company is committed to launch orforglipron globally, including in India, subject to regulatory approvals.
Earlier, Lilly’s Mounjaro, which is injected once-in-a week, was the first GLP-1 drug to enter India’s market for diabetes and weight loss.
However, Lilly did not mention any specific date for getting approval from the Indian drug regulator for selling orforglipron. The US FDA approved the weight-loss pill orforglipron on April 1, 2026. In the US, the drug is named as Foundayo.
Lilly had conducted trials for ATTAIN‑1, a global Phase 3 clinical trial evaluating orforglipron in India and other countries.
“ATTAIN‑1 was a global Phase 3 clinical trial, and India was among the countries that participated in the study,” Tucker was quoted as saying by MC.
Lilly stated that the trial results showed weight loss of up to 12.4 kg, while maintaining a safety profile consistent with injectable GLP‑1 therapies.
US FDA’s green signal for Foundayo (orforglipron)
The US Food and Drug Administration gave green signal to Foundayo (orforglipron). The US FDA in its statement said that Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
“Foundayo is a glucagon-like peptide-1 (GLP-1) receptor agonist in tablet form that should be taken orally once daily. Starting dosage is 0.8 mg, which should be increased to 2.5 mg after at least 30 days and then to 5.5 mg after another 30 days. The dosage may be increased further to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level based on treatment response and tolerability,” the statement further stated.
(Weight loss medications and other drugs should be taken only after consultation with a healthcare professional. News9 does not recommends any intake of drugs without doctor’s prescription.)
